Matches in DBpedia 2014 for { ?s ?p Cediranib (tentative trade name Recentin), also known as AZD2171, is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.It is being developed by AstraZeneca as a possible anti-cancer chemotherapeutic agent for oral administration.Beginning in 2007, it underwent Phase I clinical trials for the treatment of non-small cell lung cancer, kidney cancer, and colorectal cancer in adults, as well as tumors of the central nervous system in children.. }
Showing items 1 to 1 of
1
with 100 items per page.
- Cediranib comment "Cediranib (tentative trade name Recentin), also known as AZD2171, is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.It is being developed by AstraZeneca as a possible anti-cancer chemotherapeutic agent for oral administration.Beginning in 2007, it underwent Phase I clinical trials for the treatment of non-small cell lung cancer, kidney cancer, and colorectal cancer in adults, as well as tumors of the central nervous system in children.".